InvestSMART

AtCor Medical Holdings Limited (ASX: ACG) - Announcements

- Current share price for ACG : $0.027

ASX company news and announcements for AtCor Medical Holdings Limited (ACG) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AtCor Medical Holdings Limited (ACG) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AtCor Medical Holdings Limited (ACG), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AtCor Medical Holdings Limited (ACG)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- SphygmoCor selected for French Alzheimers trial 3 Sep 2014 9:29AM $0.095 $0.027 fallen by 71.58%
- App 4E / Full Year Statutory Accounts 28 Aug 2014 4:11PM $0.093 $0.027 fallen by 70.97%
- Market update 3 Jul 2014 4:23PM $0.099 $0.027 fallen by 72.73%
- AtCor and SunTech launch innovative ABPM for Central BP 18 Jun 2014 9:32AM $0.100 $0.027 fallen by 73%
- First SphygmoCor sales in China 2 Jun 2014 11:26AM $0.115 $0.027 fallen by 76.52%
- Patent grant in USA 16 Apr 2014 10:07AM $0.115 $0.027 fallen by 76.52%
- Study shows improved outcomes from SphygmoCor guided therapy 3 Apr 2014 11:15AM $0.125 $0.027 fallen by 78.40%
- Half Yearly Report and Accounts 20 Feb 2014 4:30PM $0.140 $0.027 fallen by 80.71%
- SphygmoCor XCEL approved for sale in Canada 30 Jan 2014 9:18AM $0.140 $0.027 fallen by 80.71%
- SphygmoCor XCEL approved for sale in China 14 Jan 2014 9:45AM $0.145 $0.027 fallen by 81.38%
- Market update 9 Jan 2014 4:20PM $0.170 $0.027 fallen by 84.12%
- ASX Price Query & Response 12 Nov 2013 8:57AM $0.180 $0.027 fallen by 85%
- US$0.6 million new pharmaceutical trial contract 28 Oct 2013 8:27AM $0.160 $0.027 fallen by 83.13%
- Appendix 4C - quarterly 23 Oct 2013 12:33PM $0.180 $0.027 fallen by 85%
- Aust study demonstrates the benefits of measuring central BP 26 Sep 2013 8:48AM $0.170 $0.027 fallen by 84.12%
- SphygmoCor XCEL approved for sale in Mexico 4 Sep 2013 9:57AM $0.125 $0.027 fallen by 78.40%
- Preliminary Final Report & Annual Accounts 30 Aug 2013 9:14AM $0.135 $0.027 fallen by 80%
- SphygmoCor XCEL approved for sale in Republic of Korea 7 Aug 2013 8:44AM $0.140 $0.027 fallen by 80.71%
- Seminal study for central pressures in clinical practice 1 Aug 2013 9:57AM $0.125 $0.027 fallen by 78.40%
- AtCor to report full year maiden profit 22 Jul 2013 8:35AM $0.105 $0.027 fallen by 74.29%
- Appendix 4C - quarterly 22 Jul 2013 8:33AM $0.105 $0.027 fallen by 74.29%
- Patent granted in Europe 15 Jul 2013 9:32AM $0.073 $0.027 fallen by 63.01%
- Appendix 4C - quarterly 23 Apr 2013 9:11AM $0.082 $0.027 fallen by 67.07%
- New study strongly supports measurement of central pressures 19 Apr 2013 9:42AM $0.089 $0.027 fallen by 69.66%
- US$0.8million pharmaceutical trial contract expansion 25 Feb 2013 9:24AM $0.100 $0.027 fallen by 73%

151 - 175 of 300 results

Page 7 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.